Cargando…

A Mathematical Model for Predicting Patient Responses to Combined Radiotherapy with CTLA-4 Immune Checkpoint Inhibitors

The purpose of this study was to develop a cell–cell interaction model that could predict a tumor’s response to radiotherapy (RT) combined with CTLA-4 immune checkpoint inhibition (ICI) in patients with hepatocellular carcinoma (HCC). The previously developed model was extended by adding a new term...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Yongjin, Choe, Bo-Young, Suh, Tae Suk, Sung, Wonmo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177154/ https://www.ncbi.nlm.nih.gov/pubmed/37174706 http://dx.doi.org/10.3390/cells12091305

Ejemplares similares

Abscopal effect of radiotherapy combined with immune checkpoint inhibitors
por: Liu, Yang, et al.
Publicado: (2018)

Combined immune checkpoint inhibitors of CTLA4 and PD-1 for hepatic melanoma of unknown primary origin: A case report
por: Cheng, An-Che, et al.
Publicado: (2021)

Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
por: Afzal, Muhammad Zubair, et al.
Publicado: (2018)

Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma
por: Li, Xiezhao, et al.
Publicado: (2017)

Nanobody-based CTLA4 inhibitors for immune checkpoint blockade therapy of canine cancer patients
por: Marable, Jonathan, et al.
Publicado: (2021)

Rational Combination of Parvovirus H1 With CTLA-4 and PD-1 Checkpoint Inhibitors Dampens the Tumor Induced Immune Silencing
por: Goepfert, Katrin, et al.
Publicado: (2019)

Radiotherapy plus immune checkpoint inhibitor in prostate cancer
por: Li, Tianjie, et al.
Publicado: (2023)

Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model
por: Lai, Xiulan, et al.
Publicado: (2017)

Protocol for mathematical prediction of patient response and survival to immune checkpoint inhibitor immunotherapy
por: Butner, Joseph D., et al.
Publicado: (2022)

Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer
por: Jungles, Kassidy M., et al.
Publicado: (2022)

Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1
por: Kong, Yi-chi M., et al.
Publicado: (2014)

Combination therapy of cancer with cancer vaccine and immune checkpoint inhibitors: A mathematical model
por: Lai, Xiulan, et al.
Publicado: (2017)

Radiotherapy and checkpoint inhibitors: a winning new combination?
por: Ko, Eric C., et al.
Publicado: (2018)

Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy
por: Rose, April A N, et al.
Publicado: (2021)

Combination therapy for mCRPC with immune checkpoint inhibitors, ADT and vaccine: A mathematical model
por: Siewe, Nourridine, et al.
Publicado: (2022)

TGFβ2 Induces the Soluble Isoform of CTLA-4 – Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma
por: Khanolkar, Rahul C., et al.
Publicado: (2022)

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
por: Qin, Shuang, et al.
Publicado: (2019)

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
por: Zhang, Hao, et al.
Publicado: (2021)

Computational design of a cyclic peptide that inhibits the CTLA4 immune checkpoint
por: Thakkar, Ravindra, et al.
Publicado: (2023)

Mathematical prediction with pretreatment growth rate of metastatic cancer on outcomes: implications for the characterization of oligometastatic disease
por: Shin, Yerim, et al.
Publicado: (2023)

Dynamic changes in the T cell receptor repertoire during treatment with radiotherapy combined with an immune checkpoint inhibitor
por: Öjlert, Åsa Kristina, et al.
Publicado: (2021)

Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors
por: Matsui, Jennifer K., et al.
Publicado: (2022)

Thyroid Immune-Related Adverse Events Among Cancer Patients Treated With Combination of Anti-PD1 and Anti-CTLA4 Immune-Checkpoint Inhibitors: Clinical Course and Outcomes
por: Lui, David T W, et al.
Publicado: (2021)

Locoregional Recurrence Prediction Using a Deep Neural Network of Radiological and Radiotherapy Images
por: Han, Kyumin, et al.
Publicado: (2022)

CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis
por: Gerdes, Lisa Ann, et al.
Publicado: (2016)

Radiotherapy as an immune checkpoint blockade combination strategy for hepatocellular carcinoma
por: Lee, Byung Min, et al.
Publicado: (2021)

Immune checkpoint inhibitors of CTLA4 and PD-1 for malignant melanoma arising in ovarian cystic teratoma: A case report
por: Yano, Mitsutake, et al.
Publicado: (2018)

Constitutive reduction in the checkpoint inhibitor, CTLA-4, does not accelerate SLE in NZM 2328 mice
por: Stohl, William, et al.
Publicado: (2019)

Immune Checkpoint Inhibitor with or without Radiotherapy in Melanoma Patients with Brain Metastases: A Systematic Review and Meta-Analysis
por: Kim, Pyeong Hwa, et al.
Publicado: (2021)

Mixed effects modeling of radiotherapy in combination with immune checkpoint blockade or inhibitors of the DNA damage response pathway
por: Hodson, David, et al.
Publicado: (2023)

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
por: Xu, Ya, et al.
Publicado: (2020)

Combination therapy for cancer with oncolytic virus and checkpoint inhibitor: A mathematical model
por: Friedman, Avner, et al.
Publicado: (2018)

The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis
por: Gu, Lihu, et al.
Publicado: (2019)

Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke
por: Belluomini, Lorenzo, et al.
Publicado: (2019)

Near-Infrared Photoimmunotherapy Combined with CTLA4 Checkpoint Blockade in Syngeneic Mouse Cancer Models
por: Maruoka, Yasuhiro, et al.
Publicado: (2020)

Immune checkpoint inhibitors for urothelial carcinoma
por: Kim, Hyung Suk, et al.
Publicado: (2018)

Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy
por: Mortensen, Rasmus Erik Johansson, et al.
Publicado: (2023)

Abnormal Expression of BTLA and CTLA-4 Immune Checkpoint Molecules in Chronic Lymphocytic Leukemia Patients
por: Karabon, L., et al.
Publicado: (2020)

Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment
por: Ziogas, Dimitrios C., et al.
Publicado: (2023)

Combined Treatment with Ultrasound and Immune Checkpoint Inhibitors for Prostate Cancer
por: Hayashi, Fuuka, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ah14q13469mtrrdabfl7d6rfss